Moleculin Biotech (MBRX) just unveiled an announcement.
Moleculin Biotech, Inc. has announced the upcoming issuance of a significant new patent, titled “Preparation of Preliposomal Annamycin Lyophilizate,” granted by the United States Patent and Trademark Office. This patent, shared with The University of Texas System Board of Regents, promises to bolster Moleculin’s intellectual property portfolio upon its issuance on April 9, 2024, potentially exciting news for investors and followers of pharmaceutical innovations.
Learn more about MBRX stock on TipRanks’ Stock Analysis page.
